Avid Bioservices Inc (CDMO)

[cjgaddy]

NCI Scientist Speaking “PS” 10-2-17 at AACR/Immunotherapy Conf. in WashDC. Traces back to same author’s 6-1-17 Mol.Cell article with basically the same name. Interesting: Both the Lead+Senior authors (NCI) list MSKCC in their work declarations.

Oct1-4 2017: “AACR’s Tumor Immunology & Immunotherapy Conf.”, Boston
http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=122
Pgm: http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=122&DetailItemID=651
10-2-17 3:45-5:30pm: Plenary Session 4: A Systems Approach to Immuno-Oncology
“Long-Lived Disruption of Inflammation Stems from the Catch-and-Release of Cytokines Mediated by Surface Phosphatidylserine in Tumors”, Gregoire Altan-Bonnet, NCI, Bethesda
G. Altan-Bonnet profile: https://ccr.cancer.gov/Cancer-and-Inflammation-Program/gr%C3%A9goire-altan-bonnet
- - - - -
Related Pub. 6-1-17/MolCell: “Catch & Release of Cytokines Mediated by Tumor Phosphatidylserine Converts Transient Exposure into Long-Lived Inflammation”, Senior Author: Gregoire Altan-Bonnet **
https://www.ncbi.nlm.nih.gov/pubmed/28575659
NCI Followup PR: “Cancer cells with more PS on their surfaces could be more vulnerable to these treatments because they will maintain high IFNy levels in the surrounding tissue.”
https://ccr.cancer.gov/news/article/catch-and-release-a-weak-point-on-cancer-cells
**INTERESTING: Memorial Sloan Kettering CC (MSKCC) is listed in the author-info. section for both Dr. G.Altan-Bonnet and the lead author, J. Oyler-Yaniv.